+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Attention Deficit Hyperactivity Disorder Market by Drug Class (Non Stimulants, Stimulants), Therapeutic Approach (Non Pharmacological, Pharmacological), End User, Distribution Channel, Age Group, Gender, Diagnosis Type - Global Forecast 2025-2030- Product Image
Attention Deficit Hyperactivity Disorder Market by Drug Class (Non Stimulants, Stimulants), Therapeutic Approach (Non Pharmacological, Pharmacological), End User, Distribution Channel, Age Group, Gender, Diagnosis Type - Global Forecast 2025-2030- Product Image
Sale

Attention Deficit Hyperactivity Disorder Market by Drug Class (Non Stimulants, Stimulants), Therapeutic Approach (Non Pharmacological, Pharmacological), End User, Distribution Channel, Age Group, Gender, Diagnosis Type - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6013867
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The worldwide Attention Deficit Hyperactivity Disorder (ADHD) market is experiencing significant transformation, driven by evolving therapies, regulatory shifts, and advances in digital health. Senior decision-makers must navigate emerging complexities to ensure competitive positioning and sustainable growth within this dynamic landscape.

Market Snapshot: Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market grew from USD 15.61 billion in 2024 to USD 16.29 billion in 2025. It is expected to continue growing at a CAGR of 4.20%, reaching USD 19.99 billion by 2030.

Scope & Segmentation

  • Drug Class: Non stimulants (atomoxetine, clonidine, guanfacine), stimulants (amphetamines, methylphenidate)
  • Therapeutic Approach: Non pharmacological (behavioral therapy, cognitive behavioral therapy, parent training, dietary supplements, neurofeedback), pharmacological (oral, transdermal)
  • End User: Clinics (inpatient, outpatient), home care (home visits, telehealth), hospitals (secondary care, tertiary care)
  • Distribution Channel: Hospital pharmacies, online pharmacies (direct to consumer, marketplace), retail pharmacies
  • Age Group: Adolescents (early, late), adults (middle aged, young), children (pre school, school age)
  • Gender: Female, male
  • Diagnosis Type: Combined, predominantly hyperactive impulsive, predominantly inattentive
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa, and more), Asia-Pacific (China, India, Japan, Australia, Southeast Asia and others)

This market also tracks significant technological solutions such as digital health tools, AI-enabled diagnostics, and integrated telemedicine platforms that enable innovative care models and patient engagement.

Key Takeaways for Decision-Makers

  • Rapid technological adoption, including digital therapeutics and AI diagnostics, is improving patient access and engagement, especially in underserved and remote settings.
  • The ADHD therapeutics landscape is diversifying, with both stimulant and nonstimulant options supporting individualized treatment pathways and addressing diverse safety and adherence needs.
  • Nonpharmacological interventions, such as behavioral therapy and cognitive training, are growing in importance alongside pharmacotherapy, offering broader, patient-centered solutions.
  • Market participants are investing in real-world evidence and value-based contracts to demonstrate measurable impacts on quality of life, academic performance, and workforce productivity.
  • Competitive dynamics reflect collaboration between pharmaceutical leaders, digital health innovators, and contract service providers, fostering the development of novel combinations and hybrid care models.
  • Regional variation in healthcare infrastructure and policy is shaping access, reimbursement, and product adoption, necessitating local market strategies and flexible distribution frameworks.

Tariff Impact: Navigating U.S. Trade Policy Shifts

The 2025 U.S. tariffs on select pharmaceutical imports are influencing sourcing, pricing strategies, and supply chain resilience in the ADHD therapeutics sector. Manufacturers and distributors are adapting through alternative sourcing, domestic capacity investments, and revised contractual arrangements. The policy shift is encouraging further industry collaboration to mitigate risks and sustain innovation despite changing trade dynamics.

Methodology & Data Sources

This report combines in-depth literature review of peer-reviewed studies, clinical trials, and government publications with primary insights from industry stakeholders—psychiatrists, therapists, payers, digital health executives, and advocacy representatives. Structured interviews and survey data inform segmentation, competitive mapping, and regional analysis, supported by expert board review to ensure data validity and relevance.

Why This Report Matters

  • Enables executives to benchmark product portfolios and investment plans against global and regional ADHD market shifts.
  • Supports strategic decisions by highlighting actionable opportunities in digital health integration, diversified supply chains, and outcome-focused growth models.
  • Equips commercial, clinical, and policy leaders with granular segmentation and competitor intelligence to guide resource allocation and regulatory preparedness.

Conclusion

The ADHD market is evolving through innovation, local adaptation, and collaborative strategies. This report offers the insights senior leaders need to define priorities, drive market expansion, and ensure resilient execution amid ongoing change.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of digital therapy platforms integrating gamification and neurofeedback for ADHD management
5.2. Emergence of plant-based nutraceutical formulations targeting cognitive focus and impulsivity in ADHD
5.3. Increasing collaborations between pediatric telehealth services and licensed ADHD specialists for remote diagnosis and treatment
5.4. Growth of AI-driven predictive analytics tools enabling personalized ADHD medication dosing and adherence monitoring
5.5. Expansion of employer-sponsored mental wellness programs incorporating ADHD screening and accommodation benefits
5.6. Regulatory advances in fast-track approval pathways accelerating novel non-stimulant ADHD drug development
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Attention Deficit Hyperactivity Disorder Market, by Drug Class
8.1. Introduction
8.2. Non Stimulants
8.2.1. Atomoxetine
8.2.2. Clonidine
8.2.3. Guanfacine
8.3. Stimulants
8.3.1. Amphetamines
8.3.2. Methylphenidate
9. Attention Deficit Hyperactivity Disorder Market, by Therapeutic Approach
9.1. Introduction
9.2. Non Pharmacological
9.2.1. Behavioral Therapy
9.2.1.1. Cognitive Behavioral Therapy
9.2.1.2. Parent Training
9.2.2. Dietary Supplements
9.2.3. Neurofeedback
9.3. Pharmacological
9.3.1. Oral
9.3.2. Transdermal
10. Attention Deficit Hyperactivity Disorder Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Inpatient
10.2.2. Outpatient
10.3. Home Care
10.3.1. Home Visits
10.3.2. Telehealth
10.4. Hospitals
10.4.1. Secondary Care
10.4.2. Tertiary Care
11. Attention Deficit Hyperactivity Disorder Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.3.1. Direct To Consumer
11.3.2. Marketplace
11.4. Retail Pharmacies
12. Attention Deficit Hyperactivity Disorder Market, by Age Group
12.1. Introduction
12.2. Adolescents
12.2.1. Early Adolescents
12.2.2. Late Adolescents
12.3. Adults
12.3.1. Middle Aged Adults
12.3.2. Young Adults
12.4. Children
12.4.1. Pre School
12.4.2. School Age
13. Attention Deficit Hyperactivity Disorder Market, by Gender
13.1. Introduction
13.2. Female
13.3. Male
14. Attention Deficit Hyperactivity Disorder Market, by Diagnosis Type
14.1. Introduction
14.2. Combined
14.3. Predominantly Hyperactive Impulsive
14.4. Predominantly Inattentive
15. Americas Attention Deficit Hyperactivity Disorder Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Attention Deficit Hyperactivity Disorder Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Attention Deficit Hyperactivity Disorder Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Takeda Pharmaceutical Company Limited
18.3.2. Johnson & Johnson
18.3.3. Teva Pharmaceutical Industries Ltd
18.3.4. Novartis International AG
18.3.5. Eli Lilly and Company
18.3.6. Pfizer Inc.
18.3.7. Viatris Inc.
18.3.8. Sandoz International GmbH
18.3.9. Sun Pharmaceutical Industries Ltd
18.3.10. Akili Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: RESEARCHAI
FIGURE 30. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: RESEARCHSTATISTICS
FIGURE 31. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: RESEARCHCONTACTS
FIGURE 32. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ATOMOXETINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ATOMOXETINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLONIDINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLONIDINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GUANFACINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GUANFACINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AMPHETAMINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PARENT TRAINING, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PARENT TRAINING, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NEUROFEEDBACK, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NEUROFEEDBACK, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME VISITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TELEHEALTH, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SECONDARY CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SECONDARY CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY TERTIARY CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MARKETPLACE, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MARKETPLACE, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY EARLY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY EARLY ADOLESCENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY LATE ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY LATE ADOLESCENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MIDDLE AGED ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MIDDLE AGED ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PRE SCHOOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PRE SCHOOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SCHOOL AGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SCHOOL AGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY FEMALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY FEMALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MALE, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY MALE, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COMBINED, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COMBINED, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PREDOMINANTLY HYPERACTIVE IMPULSIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PREDOMINANTLY HYPERACTIVE IMPULSIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PREDOMINANTLY INATTENTIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PREDOMINANTLY INATTENTIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 215. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2024 (USD MILLION)
TABLE 218. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2025-2030 (USD MILLION)
TABLE 219. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2024 (USD MILLION)
TABLE 220. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2025-2030 (USD MILLION)
TABLE 221. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 222. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 223. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 224. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 225. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
TABLE 226. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2030 (USD MILLION)
TABLE 227. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 228. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 229. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 232. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 233. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 234. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 235. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 236. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 237. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 240. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 241. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2018-2024 (USD MILLION)
TABLE 244. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADOLESCENTS, 2025-2030 (USD MILLION)
TABLE 245. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2018-2024 (USD MILLION)
TABLE 246. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ADULTS, 2025-2030 (USD MILLION)
TABLE 247. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2018-2024 (USD MILLION)
TABLE 248. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CHILDREN, 2025-2030 (USD MILLION)
TABLE 249. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2018-2024 (USD MILLION)
TABLE 250. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY GENDER, 2025-2030 (USD MILLION)
TABLE 251. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2018-2024 (USD MILLION)
TABLE 252. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DIAGNOSIS TYPE, 2025-2030 (USD MILLION)
TABLE 253. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2018-2024 (USD MILLION)
TABLE 256. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON STIMULANTS, 2025-2030 (USD MILLION)
TABLE 257. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2018-2024 (USD MILLION)
TABLE 258. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, 2025-2030 (USD MILLION)
TABLE 259. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 260. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 261. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 262. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 263. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2024 (USD MILLION)
TABLE 264. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, 2025-2030 (USD MILLION)
TABLE 265. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2018-2024 (USD MILLION)
TABLE 266. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOLOGICAL, 2025-2030 (USD MILLION)
TABLE 267. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
TABLE 272. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOME CARE, 2025-2030 (USD MILLION)
TABLE 273. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 274. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 275. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
TABLE 278. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, 2025-2030 (USD MILLION)
TABLE 279. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. MEXICO ATT

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Attention Deficit Hyperactivity Disorder market report include:
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd
  • Novartis International AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd
  • Akili Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.29 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.99 Billion
Compound Annual Growth Rate4.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Attention-Deficit Hyperactivity Disorder Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Attention-Deficit Hyperactivity Disorder Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2025 - Product Image

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Attention Deficit Hyperactivity Disorder Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report - Product Image

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From
Attention Deficit Hyperactivity Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Attention Deficit Hyperactivity Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 271 Pages
  • Global
From

About the Attention Deficit Hyperactivity Disorder Drug Market

Attention Deficit Hyperactivity Disorder (ADHD) is a mental disorder that affects a person's ability to focus and control their behavior. Mental Disorders Drugs are used to treat the symptoms of ADHD, such as difficulty concentrating, impulsivity, and hyperactivity. Stimulant medications are the most commonly prescribed drugs for ADHD, and they work by increasing the levels of dopamine and norepinephrine in the brain. Non-stimulant medications, such as atomoxetine, are also used to treat ADHD. The ADHD Drug market is highly competitive, with a number of pharmaceutical companies offering various medications. Companies such as Eli Lilly, Shire, Novartis, and Pfizer are some of the major players in the market. Other companies such as Teva Pharmaceuticals, Sun Pharmaceuticals, and Mylan also offer ADHD medications. These companies are constantly innovating and developing new drugs to meet the needs of patients with ADHD. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.